Evidence map›Paper›PMID 32502148›Full record

ArticlePLoS computational biology2020

Epidemiological consequences of enduring strain-specific immunity requiring repeated episodes of infection.

Rebecca H Chisholm, Nikki Sonenberg, Jake A Lacey, Malcolm I McDonald, Manisha Pandey, Mark R Davies, Steven Y C Tong, Jodie McVernon, Nicholas Geard

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Rebecca H ChisholmDepartment of Mathematics and Statistics, La Trobe University, Melbourne, Victoria, Australia.ORCID 0000-0002-7830-793X
Nikki SonenbergCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-2133-9842
Jake A LaceyDoherty Department University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.ORCID 0000-0002-6492-6983
Malcolm I McDonaldAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, Queensland, Australia.ORCID 0000-0002-7225-8671
Manisha PandeyInstitute for Glycomics, Gold Coast Campus, Griffith University, Brisbane, Queensland, Australia.
Mark R DaviesDepartment of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0001-6141-5179
Steven Y C TongDoherty Department University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.ORCID 0000-0002-1368-8356
Jodie McVernonVictorian Infectious Diseases Reference Laboratory Epidemiology Unit at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Victoria, Australia.ORCID 0000-0001-9774-1961
Nicholas GeardVictorian Infectious Diseases Reference Laboratory Epidemiology Unit at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Victoria, Australia.
The University of Melbourne · AUThe Royal Melbourne Hospital · AUAustralian Institute of Tropical Health and Medicine · AUGriffith University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Group A Streptococcus (GAS) skin infections are caused by a diverse array of strain types and are highly prevalent in disadvantaged populations. The role of strain-specific immunity in preventing GAS infections is poorly understood, representing a critical knowledge gap in vaccine development. A recent GAS murine challenge study showed evidence that sterilising strain-specific and enduring immunity required two skin infections by the same GAS strain within three weeks. This mechanism of developing enduring immunity may be a significant impediment to the accumulation of immunity in populations. We used an agent-based mathematical model of GAS transmission to investigate the epidemiological consequences of enduring strain-specific immunity developing only after two infections with the same strain within a specified interval. Accounting for uncertainty when correlating murine timeframes to humans, we varied this maximum inter-infection interval from 3 to 420 weeks to assess its impact on prevalence and strain diversity, and considered additional scenarios where no maximum inter-infection interval was specified. Model outputs were compared with longitudinal GAS surveillance observations from northern Australia, a region with endemic infection. We also assessed the likely impact of a targeted strain-specific multivalent vaccine in this context. Our model produced patterns of transmission consistent with observations when the maximum inter-infection interval for developing enduring immunity was 19 weeks. Our vaccine analysis suggests that the leading multivalent GAS vaccine may have limited impact on the prevalence of GAS in populations in northern Australia if strain-specific immunity requires repeated episodes of infection. Our results suggest that observed GAS epidemiology from disease endemic settings is consistent with enduring strain-specific immunity being dependent on repeated infections with the same strain, and provide additional motivation for relevant human studies to confirm the human immune response to GAS skin infection.

Indexed as

Streptococcus pyogenesAnimalsAustraliaBasic Reproduction NumberDisease Models, AnimalHumansMiceModels, TheoreticalPopulation DynamicsPopulation GroupsSkin DiseasesStreptococcal InfectionsStreptococcal VaccinesStreptococcal Vaccines

Identifiers

PMID32502148
PMCPMC7299408
OpenAlexW3033855543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.